BRCA-话题@MedSci - williamhill asia

#BRCA#

135篇内容 | 2423人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2218358, encodeId=2f9f2218358c5, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a> <a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=【衡道丨笔记】卵巢癌分子病理研究进展, objectType=article, longId=837354, objectId=b69983e35480, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240725/1721901351109_8538692.png, objectUrl=/article/show_article.do?id=b69983e35480, replyNumber=0, likeNumber=5, createdTime=2024-08-03, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b69983e35480, moduleTitle=【衡道丨笔记】卵巢癌分子病理研究进展, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b69983e35480)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2189261, encodeId=b902218926106, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a> <a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a> <a href='/topic/show?id=0d751115294f' target=_blank style='color:#2F92EE;'>#铂敏感复发性卵巢癌#</a>, objectTitle=Gynecol. Oncol | 尼拉帕利在铂敏感复发性卵巢癌维持治疗的真实世界研究, objectType=article, longId=814633, objectId=6af381463392, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240225/1708830948258_6145188.png, objectUrl=/article/show_article.do?id=6af381463392, replyNumber=0, likeNumber=54, createdTime=2024-02-25, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=湖北省, moduleDTOList=[ModuleDTO(moduleId=6af381463392, moduleTitle=Gynecol. Oncol | 尼拉帕利在铂敏感复发性卵巢癌维持治疗的真实世界研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6af381463392)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1594098, encodeId=90c915940986e, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, objectType=article, longId=739077, objectId=6949e390775b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6949e390775b, replyNumber=0, likeNumber=83, createdTime=2022-09-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6949e390775b, moduleTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6949e390775b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594097, encodeId=839f159409e96, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Nature Communications：浙大谢安勇团队揭示BRCA1缺陷肿瘤特征性突变模式发生来源与机制, objectType=article, longId=735965, objectId=4c40e3596563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c40e3596563, replyNumber=0, likeNumber=79, createdTime=2022-08-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c40e3596563, moduleTitle=Nature Communications：浙大谢安勇团队揭示BRCA1缺陷肿瘤特征性突变模式发生来源与机制, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4c40e3596563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594096, encodeId=50ff15940968a, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Nat Commun：HMMR过表达增加BRCA1相关乳腺癌患病风险, objectType=article, longId=724006, objectId=2732e2400679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2732e2400679, replyNumber=0, likeNumber=49, createdTime=2022-04-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2732e2400679, moduleTitle=Nat Commun：HMMR过表达增加BRCA1相关乳腺癌患病风险, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2732e2400679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594095, encodeId=0d8b159409526, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, objectType=article, longId=723981, objectId=f235e2398163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f235e2398163, replyNumber=0, likeNumber=90, createdTime=2022-04-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f235e2398163, moduleTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f235e2398163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594094, encodeId=30131594094ce, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险, objectType=article, longId=301442, objectId=1e71301442a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e71301442a7, replyNumber=0, likeNumber=64, createdTime=2022-03-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e71301442a7, moduleTitle=J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1e71301442a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594093, encodeId=7d51159409382, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择, objectType=article, longId=300992, objectId=cea030099207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cea030099207, replyNumber=0, likeNumber=106, createdTime=2022-03-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cea030099207, moduleTitle=Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cea030099207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594092, encodeId=8ce6159409280, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, objectType=article, longId=295703, objectId=ea9c295e0337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea9c295e0337, replyNumber=0, likeNumber=55, createdTime=2022-02-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea9c295e0337, moduleTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ea9c295e0337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594091, encodeId=27ec159409130, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效, objectType=article, longId=295135, objectId=2c9b295135ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c9b295135ea, replyNumber=0, likeNumber=82, createdTime=2022-02-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c9b295135ea, moduleTitle=Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2c9b295135ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594090, encodeId=594a15940901a, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效, objectType=article, longId=221327, objectId=bdda22132edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdda22132edc, replyNumber=0, likeNumber=74, createdTime=2021-12-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdda22132edc, moduleTitle=Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bdda22132edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594089, encodeId=3014159408932, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌的疗效, objectType=article, longId=218868, objectId=6faf2188681d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6faf2188681d, replyNumber=0, likeNumber=0, createdTime=2021-10-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6faf2188681d, moduleTitle=Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6faf2188681d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594088, encodeId=dacd1594088e8, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=JAMA Oncol：BRCA1/2 基因突变携带者预防性输卵管切除术，术后生活质量仍然良好, objectType=article, longId=217455, objectId=556e21e455f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556e21e455f3, replyNumber=0, likeNumber=59, createdTime=2021-09-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556e21e455f3, moduleTitle=JAMA Oncol：BRCA1/2 基因突变携带者预防性输卵管切除术，术后生活质量仍然良好, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=556e21e455f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594087, encodeId=21b0159408e09, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Clin Cancer Res：尼拉帕利治疗携带BRCA1/2胚系突变的晚期乳腺癌的疗效, objectType=article, longId=216770, objectId=e27f216e703d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e27f216e703d, replyNumber=0, likeNumber=63, createdTime=2021-09-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e27f216e703d, moduleTitle=Clin Cancer Res：尼拉帕利治疗携带BRCA1/2胚系突变的晚期乳腺癌的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e27f216e703d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594086, encodeId=9b791594086af, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Br J Cancer：CD4、CD8和 FOXP3阳性免疫细胞可作为BRCA1/2相关乳腺癌死亡率的预测标志物, objectType=article, longId=215568, objectId=10ce21556891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10ce21556891, replyNumber=0, likeNumber=79, createdTime=2021-08-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10ce21556891, moduleTitle=Br J Cancer：CD4、CD8和 FOXP3阳性免疫细胞可作为BRCA1/2相关乳腺癌死亡率的预测标志物, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=10ce21556891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594085, encodeId=784415940859f, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌中的治疗活性, objectType=article, longId=214713, objectId=e63f214e13a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e63f214e13a8, replyNumber=0, likeNumber=80, createdTime=2021-07-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e63f214e13a8, moduleTitle=Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌中的治疗活性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e63f214e13a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594084, encodeId=0f7a159408418, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=BRCA1/2突变的年轻患者是否适宜保乳手术？, objectType=article, longId=213883, objectId=856a2138838e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=856a2138838e, replyNumber=0, likeNumber=88, createdTime=2021-07-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=856a2138838e, moduleTitle=BRCA1/2突变的年轻患者是否适宜保乳手术？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=856a2138838e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594083, encodeId=8715159408344, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=NEJM：奥拉帕利辅助治疗BRCA阳性早期乳腺癌, objectType=article, longId=213281, objectId=268e21328176, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=268e21328176, replyNumber=0, likeNumber=0, createdTime=2021-06-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=268e21328176, moduleTitle=NEJM：奥拉帕利辅助治疗BRCA阳性早期乳腺癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=268e21328176)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594082, encodeId=562f1594082a0, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Eur J Cancer：奥拉帕利单药治疗gBRCAm-HER2阴性转移性乳腺癌的实际临床疗效, objectType=article, longId=212462, objectId=1f99212462e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f99212462e3, replyNumber=0, likeNumber=100, createdTime=2021-06-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f99212462e3, moduleTitle=Eur J Cancer：奥拉帕利单药治疗gBRCAm-HER2阴性转移性乳腺癌的实际临床疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1f99212462e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594081, encodeId=c485159408199, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, objectTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, objectType=article, longId=211652, objectId=9a1e21165207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1e21165207, replyNumber=0, likeNumber=75, createdTime=2021-05-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1e21165207, moduleTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=9a1e21165207)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

BRCA

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#卵巢癌# #BRCA#

【衡道丨笔记】卵巢癌分子病理研究进展

2024-08-03发表于上海

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#BRCA# #尼拉帕利# #铂敏感复发性卵巢癌#

Gynecol. Oncol | 尼拉帕利在铂敏感复发性卵巢癌维持治疗的真实世界研究

2024-02-25发表于湖北省

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）

2022-09-13

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Nature Communications：浙大谢安勇团队揭示BRCA1缺陷肿瘤特征性突变模式发生来源与机制

2022-08-17

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Nat Commun：HMMR过表达增加BRCA1相关乳腺癌患病风险

2022-04-12

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验

2022-04-12

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险

2022-03-24

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lancet Oncol：鲁卡帕利可作为BRCA1/2突变的复发性卵巢癌化疗的替代选择

2022-03-18

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效

2022-02-17

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Front Oncol：新辅助化疗对卵巢癌伴有BRCA1/2不同突变状态患者的疗效

2022-02-06

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Eur J Cancer：Rucaparib治疗BRCA1/2野生型转移性乳腺癌的疗效

2021-12-01

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌的疗效

2021-10-20

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

JAMA Oncol：BRCA1/2 基因突变携带者预防性输卵管切除术，术后生活质量仍然良好

2021-09-24

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Clin Cancer Res：尼拉帕利治疗携带BRCA1/2胚系突变的晚期乳腺癌的疗效

2021-09-08

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Br J Cancer：CD4、CD8和 FOXP3阳性免疫细胞可作为BRCA1/2相关乳腺癌死亡率的预测标志物

2021-08-12

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Clin Cancer Res：尼拉帕利在携带BRCA1/2胚系突变的晚期乳腺癌中的治疗活性

2021-07-25

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

BRCA1/2突变的年轻患者是否适宜保乳手术？

2021-07-09

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

NEJM：奥拉帕利辅助治疗BRCA阳性早期乳腺癌

2021-06-28

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Eur J Cancer：奥拉帕利单药治疗gBRCAm-HER2阴性转移性乳腺癌的实际临床疗效

2021-06-10

智智灵药 (审核中...)

前往app查看评论内容

#BRCA#

Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期

2021-05-23

科室
- - 订阅+
  - 更多科室
工具
服务